EGFR and non-small cell lung carcinoma: The discovery of oncogenic drivers in advanced NSCLC, particularly the epidermal growth factor receptor (EGFR), has paved the way for the development of tyrosine kinase inhibitors (TKIs), which significantly improve progression-free survival in NSCLC patients[3].